The stock of Pernix Therapeutics Holdings Inc (NASDAQ:PTX) is a huge mover today! About 128,630 shares traded hands. Pernix Therapeutics Holdings Inc (NASDAQ:PTX) has declined 70.83% since April 4, 2016 and is downtrending. It has underperformed by 71.92% the S&P500.
The move comes after 7 months positive chart setup for the $28.12 million company. It was reported on Nov, 4 by Barchart.com. We have $4.78 PT which if reached, will make NASDAQ:PTX worth $10.40 million more.
Pernix Therapeutics Holdings Inc (NASDAQ:PTX) Ratings Coverage
Out of 4 analysts covering Pernix Therapeutics (NASDAQ:PTX), 1 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 25% are positive. Pernix Therapeutics has been the topic of 9 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The company was downgraded on Thursday, March 17 by Oppenheimer. The stock of Pernix Therapeutics Holdings Inc (NASDAQ:PTX) earned “Buy” rating by Brean Capital on Tuesday, February 9. The stock of Pernix Therapeutics Holdings Inc (NASDAQ:PTX) has “Strong Buy” rating given on Friday, August 7 by Needham. The company was downgraded on Friday, March 11 by Needham. Brean Capital maintained Pernix Therapeutics Holdings Inc (NASDAQ:PTX) on Friday, August 7 with “Buy” rating. JMP Securities reinitiated the shares of PTX in a report on Wednesday, September 9 with “Market Outperform” rating. Brean Capital maintained it with “Buy” rating and $5 target price in Friday, March 11 report. On Friday, August 12 the stock rating was downgraded by Brean Capital to “Hold”.
According to Zacks Investment Research, “Pernix Therapeutics Holdings Inc., formerly known as Golf Trust of America, Inc., is a specialty pharmaceutical company focused on developing and commercializing pharmaceutical products to meet medical needs primarily in pediatrics. The Company’s product families include Aldex, Pediatex, Z-Cof, Brovex, ReZyst and QuinZyme. Its ALDEX products are indicated for the treatment of allergies and symptoms of the common cold. PEDIATEX TD is for the treatment of respiratory allergies. Z-COF 8DM is for the treatment of allergies and symptoms of the common cold. The BROVEX products are indicated for the treatment of allergies and symptoms of the common cold. REZYST IM is a chewable tablet probiotic indicated to replace active cultures that are destroyed by diet and antibiotics and to reduce symptoms associated with irritable bowel syndrome and various gastrointestinal issues. QUINZYME is a dissolve tablet for patients with depleted ubiquinone levels and for patients on statin therapy. Pernix is based in Magnolia, Texas.”
Insitutional Activity: The institutional sentiment decreased to 0.34 in 2016 Q2. Its down 0.41, from 0.75 in 2016Q1. The ratio worsened, as 38 funds sold all Pernix Therapeutics Holdings Inc shares owned while 21 reduced positions. 8 funds bought stakes while 12 increased positions. They now own 12.25 million shares or 66.36% less from 36.43 million shares in 2016Q1.
Goodwin Daniel L last reported 22,679 shares in the company. Goldman Sachs Gru has 237,364 shares for 0% of their US portfolio. Panagora Asset reported 8,474 shares or 0% of all its holdings. Deutsche Natl Bank Ag holds 0% or 1 shares in its portfolio. Nelson Van Denburg And Campbell Wealth Management Group Limited Liability Co accumulated 0% or 700 shares. Tudor Inv Et Al last reported 215,800 shares in the company. Guggenheim Capital Ltd Liability has 11,827 shares for 0% of their US portfolio. Millennium Mgmt Limited Liability last reported 260,033 shares in the company. Bancorp Of Montreal Can accumulated 49 shares or 0% of the stock. Geode Cap Mgmt Llc last reported 209,535 shares in the company. Highland Cap Ltd Com holds 0% or 41,000 shares in its portfolio. National Bank Of America De accumulated 0% or 107,686 shares. The New York-based Oppenheimer & Co has invested 0% in Pernix Therapeutics Holdings Inc (NASDAQ:PTX). Morgan Stanley reported 175,592 shares or 0% of all its holdings. New York State Common Retirement Fund holds 0% of its portfolio in Pernix Therapeutics Holdings Inc (NASDAQ:PTX) for 19,800 shares.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.